Loading Analysis...
Preparing AI insights for you
Preparing AI insights for you
ABBV
Avg. Confidence: 82%
Insights from 4 Leading AI Models • Updated March 3, 2026
Fundamentally, ABBV's growth narrative is strengthening with positive Phase 3 SKYRIZI data for Crohn's disease, offsetting high valuation concerns as it trades near the average target of $256.15.
Sentiment remains strongly bullish driven by new SKYRIZI approvals and dividend appeal, continuing the positive trend from March 2026.
Long-term outlook is robust due to pipeline diversification away from Humira, though regulatory execution risks remain for the new SKYRIZI indications.
Price action is likely constrained near the average target of $256.15, with the $223.00 low offering strong technical support.
Automated technical analysis based on TradingView's proprietary algorithm using multiple indicators (RSI, MACD, Moving Averages, etc.). This analysis may differ from our AI sentiment analysis above, which is based on news and fundamental factors.
Disclaimer: This analysis is generated by AI models and is for informational purposes only. It should not be considered as financial advice. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.